Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

Arcus Capital Partners LLC grew its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM) by 31.7% during the fourth quarter, ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the ...

H.C. Wainwright lowered the firm’s price target on Arcus Biosciences (RCUS) to $18 from $20 and keeps a Buy rating on the shares after the ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Arcus Biosciences (NYSE:RCUS) shares dipped 4% after the company priced a stock offering to raise approximately $150 million. The offering consists of 13,636,364 shares of common stock issued at ...